Welcome to our dedicated page for Collegium Pharmaceutical news (Ticker: COLL), a resource for investors and traders seeking the latest updates and insights on Collegium Pharmaceutical stock.
News about Collegium Pharmaceutical, Inc. (Nasdaq: COLL) focuses on its activities as a biopharmaceutical company with a portfolio spanning responsible pain management and neuropsychiatry. The company regularly issues press releases on product-related research, financial performance, capital structure, and corporate initiatives, providing investors and healthcare professionals with insight into its operations.
A major theme in Collegium’s news flow is the development and commercialization of JORNAY PM, a central nervous system stimulant indicated for the treatment of ADHD in people 6 years of age and older. The company highlights real-world data on JORNAY PM at scientific meetings such as the American Professional Society of ADHD and Related Disorders (APSARD), the American Academy of Child & Adolescent Psychiatry, and the Neuroscience Education Institute conferences. Releases describe poster presentations on dosing, comparative outcomes versus other ADHD treatments, and changes in functioning and psychiatric symptoms in various patient groups.
Collegium also issues news on its pain portfolio, including BELBUCA and XTAMPZA ER. At events like PAINWeek, the company presents multiple posters that examine treatment characteristics, safety, economic burden, and clinical outcomes for patients with chronic pain. These communications underscore Collegium’s focus on responsible pain management and real-world evidence generation.
Investors following COLL can find regular updates on quarterly financial results, guidance, and non-GAAP metrics such as adjusted EBITDA in the company’s earnings press releases. Additional news covers capital deployment, including share repurchase authorizations and the closing of a syndicated credit facility, as well as participation in healthcare and investor conferences. For those tracking developments in ADHD treatment and opioid-based pain therapies, the Collegium news page offers an organized view of clinical data, commercial progress, and financial disclosures over time.
Collegium (Nasdaq: COLL) will present four real‑world data posters on its ADHD product Jornay PM at the APSARD Annual Conference, Jan 15–18, 2026, in San Diego.
Poster session: Jan 17, 2026, 11:45 a.m.–12:45 p.m. PT at Manchester Grand Hyatt, Seaport E. Posters (Nos. 73–76) cover dosing, comparative risks/benefits with Concerta, morning/evening functioning in youth, and depression/anxiety outcomes in adults.
Collegium (NASDAQ: COLL) provided 2026 financial guidance and a business update on Jan 8, 2026. The company expects product net revenues of $805M–$825M, Jornay PM net revenue of $190M–$200M, and adjusted EBITDA of $455M–$475M for full-year 2026. Collegium closed a $980M syndicated credit facility in December 2025, used in part to repay $581M of its prior term loan, yielding immediate annualized interest savings. The company also announced an authorized generic supply agreement with Hikma, with planned Nucynta ER AG launch in Q1 2026 and broader AG timing tied to third-party generics.
Collegium (Nasdaq: COLL) closed a five-year, $980 million inaugural syndicated credit facility maturing in 2030. The facility includes a $580M initial term loan, a $300M delayed draw term loan (undrawn at closing), and a $100M revolving credit facility (undrawn at closing).
Collegium used the initial term loan to repay approximately $581M of principal on its prior $646M term loan. Interest is set at SOFR plus 2.75%–3.75% based on first lien net leverage, with the closing rate at SOFR+2.75%. The company expects this refinancing to produce meaningful annualized interest savings and provide capital flexibility for general corporate purposes and business development. Truist Bank acted as administrative agent; a syndicate of banks served as arrangers and agents.
Collegium (Nasdaq: COLL) announced management will participate in three investor conferences in Nov–Dec 2025.
Jefferies London Healthcare Conference presentation: Nov 19, 2025 at 8:00 a.m. GMT in London; webcast available via the Investors section and replay archived for 90 days.
Piper Sandler 37th Annual Healthcare Conference fireside chat: Dec 2, 2025 at 2:30 p.m. ET in New York; webcast available via the Investors section and replay archived for 90 days.
Evercore Healthcare Conference: Dec 4, 2025 in Coral Gables, FL; details and webcasts available from the Investors section.
Collegium (Nasdaq: COLL) reported record Q3 2025 net revenue of $209.4M, up 31% year‑over‑year, and raised full‑year 2025 net revenue guidance to $775–$785M. The company posted Q3 adjusted EBITDA of $133.0M (up 27% YoY) and raised adjusted EBITDA guidance to $460–$470M. Jornay PM net revenue was $41.8M in Q3 with prescriptions up 20% YoY and 27,700 prescribers (up 22% YoY). The pain portfolio generated a record $167.6M in Q3. Collegium ended the quarter with $285.9M in cash, cash equivalents and marketable securities and generated $78.4M in operating cash flow.
Collegium Pharmaceutical (Nasdaq: COLL) announced a collaboration with entrepreneur and advocate Paris Hilton to share her personal ADHD journey and treatment experience on Oct 29, 2025.
The campaign aims to reduce stigma and encourage patients to talk with healthcare providers about treatment options. The release notes ADHD prevalence estimates of 15.5 million adults and 6.5 million children in the U.S., with ~70% of cases persisting into adulthood. Paris Hilton described being diagnosed as a young adult and choosing treatment with JORNAY PM (methylphenidate HCl) ER, a nighttime-dosed stimulant that starts on waking and lasts through the day.
Collegium Pharmaceutical (Nasdaq: COLL) announced it will report third quarter 2025 financial results before the market opens on Thursday, November 6, 2025. The company will host a live conference call and webcast at 8:00 a.m. ET following the release.
Conference call dial-in numbers are (877) 407-8037 (U.S.) and (201) 689-8037 (International) referencing the “Collegium Pharmaceutical Q3 2025 Earnings Call.” An audio webcast and a replay will be available from the Investors section of the company website at www.collegiumpharma.com, with the replay posted about two hours after the event.
Collegium Pharmaceutical (Nasdaq: COLL) will present real-world data posters on its ADHD product Jornay PM at two fall conferences during ADHD Awareness Month.
At AACAP in Chicago (October 20-25, 2025) a poster titled "Determining the Optimal Dose of Methylphenidate HCl (JORNAY PM) in Adolescents and Adults" is scheduled for Oct 22, 4–6 p.m. CDT at Hyatt Regency. At NEI Fall Congress in Colorado Springs (Nov 6-9, 2025) a poster titled "JORNAY PM in Practice: Real-World Evidence Exploration of Utilization and Patient Response" is scheduled for Nov 7, 4–5 p.m. MST at Broadmoor West.
Important safety note: JORNAY PM is a Schedule II controlled stimulant with abuse, dependence, and cardiovascular and psychiatric risks; see prescribing information for details.
Collegium (Nasdaq: COLL) will ring the Nasdaq opening bell on October 14, 2025 at 9:30 a.m. ET to celebrate its 10-year anniversary as a publicly traded company.
The company highlighted its expansion into neuropsychiatry via the acquisition of Jornay PM for ADHD, noting Jornay PM is currently the fastest growing stimulant medicine for ADHD. Collegium said its financial strength, business development track record, and commercial expertise position it to continue serving patients and pursuing growth. A live stream of the Nasdaq opening bell will be available at the Nasdaq bell-ringing page.
Collegium Pharmaceutical (Nasdaq: COLL) has announced its participation in three upcoming investor conferences in September 2025. The company will attend the 2025 Wells Fargo Healthcare Conference on September 4 in Boston, participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on September 8 at 2:35 p.m. ET in New York, and present at the H.C. Wainwright Global Investment Conference on September 9 at 10:30 a.m. ET in New York.
Live webcasts of the fireside chats will be accessible through Collegium's investor relations website, with replays available for 90 days after the presentations.
FAQ
What is the current stock price of Collegium Pharmaceutical (COLL)?
What is the market cap of Collegium Pharmaceutical (COLL)?
